Program
ivacaftor
Also written as “IVA”, “Ivacaftor” and “ELX/TEZ/IVA”.
Its studies are mostly in Cystic Fibrosis · Ciliary Motility Disorders, led by 3 companies.
Drug pageIvacaftor: every studyAll 94 studies of it, academic ones too, with its approvals, label and forms.Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Vertex Pharmaceuticalsits history only | 744 open or running | phase 4since Aug 15, 2016 | Apr 5, 2007 | Apr 6, 2027phase 3 · NCT05331183 |
| Sun Pharmaceutical Industries | 30 open or running | phase 1since Mar 5, 2015 | Mar 5, 2015 | none ahead |
| Parion Sciencesits history only | 10 open or running | phase 2since Aug 12, 2016 | Aug 12, 2016 | none ahead |
How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.
History and studies of Sun Pharmaceutical Industries only; the figures above count every company.
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
- Mar 5, 2015First study: phase 1 study in HealthyFirst studyNCT02392702 · 15 enrolled · Australia
- Nov 5, 2015Phase 1 study in HealthyNCT02599792 · 37 enrolled · Australia
- Feb 3, 2016Phase 1 study in HealthyNCT02680249 · 15 enrolled · Australia
TargetBeta
“Cystic fibrosis transmembrane conductance regulator positive modulator; Cystic fibrosis transmembrane conductance regulator activator”ChEMBL 37, by rule
Other programs on CFTR
| Program | Company | Furthest phase | Studies |
|---|---|---|---|
| lumacaftorrule | Vertex Pharmaceuticals | phase 4 | 23 |
| tezacaftorrule | Vertex Pharmaceuticals | phase 3 | 39 |
Studies
All 3 Sun Pharmaceutical Industries leads, newest first. Each opens its study page.
| Study | Phase | Status | Primary completion | Size |
|---|---|---|---|---|
| NCT02680249Healthy · Australia | 1 | Completed | Apr 2016 | 15 |
| NCT02599792Healthy · Australia | 1 | Completed | Apr 2016 | 37 |
| NCT02392702Healthy · Australia | 1 | Completed | Jun 2015 | 15 |
How it is read
Names in the registry
- “IVA”, 26 entries
- “Ivacaftor”, 26 entries
- “ELX/TEZ/IVA”, 14 entries
- “VX-770”, 10 entries
- “LUM/IVA”, 8 entries
Codes read as this program: VX770.
Conditions, from the studies’ own filings
- Cystic Fibrosis, 74 studies
- Ciliary Motility Disorders, 1 study
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.